机构名称：
¥ 1.0
Dose Escalation Phase: Histologically/cytologically-proven locally advanced or metastatic solid tumors for which no standard therapy exists or standard therapy has failed • HER2 expression by IHC and/or erbb2 amplification and/or erbb2-activating mutations Dose Expansion Phase: • UBC Cohort: must have received only 1L platinum-containing regimen for inoperable locally advanced/metastatic最后剂量•MBC队列后6个月，尿路上皮癌：转移性疾病的细胞毒性疗法不超过3种先前的细胞毒性疗法•Basket（HER2 3+）同伴：活检中的HER2 3+ <6个月•胃和食管队列：仅接受了1L中的胃和食管。不包括MSI-H。如果HER2在6个月内必须在抗PDL1下进行•NSCLC队列：必须在白金治疗后6个月内在铂duunum Doublet上进行进展，或者在W/中进展。如果HER2低于6个月内的抗PDL1，则必须在抗PDL1下进行。
肝胆临床试验PI CRC协议编号和标题...
主要关键词
相关文件推荐
